The in vivo pharmacodynamics of the novel opioid receptor antagonist, TD-1211, in models of opioid-induced gastrointestinal and CNS activity

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 386, Issue 6, 2013, Pages 471-478

  Armstrong, Scott R ^a   Campbell, Christina B ^a   Richardson, Carrie L ^a   Vickery, Ross G ^a   Tsuruda, Pamela R ^a   Long, Daniel D ^a   Hegde, Sharath S ^a   Beattie, David T ^a  

^a THERAVANCE INC   (United States)

Author keywords

ADL 08 0011; Alvimopan; Constipation; Naltrexone; Opioid receptor; TD 1211

Indexed keywords

ADL 08 0011; ADL 080011; ALVIMOPAN; CASTOR OIL; LOPERAMIDE; MORPHINE; NALTREXONE; NARCOTIC AGENT; OPIATE; OPIATE ANTAGONIST; TD 1211; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CENTRAL NERVOUS SYSTEM FUNCTION; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DOG; DRUG POTENCY; GASTROINTESTINAL TRACT FUNCTION; HOT PLATE TEST; HYPOTHERMIA; IN VIVO STUDY; NONHUMAN; PHARMACODYNAMICS; RAT; SEDATION; SMOOTH MUSCLE CONTRACTILITY; STOMACH EMPTYING;

ADMINISTRATION, ORAL; ANALGESICS, OPIOID; ANIMALS; BENZAMIDES; CENTRAL NERVOUS SYSTEM; DOGS; FEMALE; GASTROINTESTINAL TRACT; MALE; MICE; MORPHINE; NALTREXONE; NARCOTIC ANTAGONISTS; PAIN; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANCE WITHDRAWAL SYNDROME; TROPANES;

EID: 84878014922     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-013-0844-5     Document Type: Article

References (31)

1. Baker A, Meert T (2002) Functional effects of systemically administered agonists and antagonists of μ, δ, and κ opioid receptor subtypes on body temperature in mice. J Pharm Exp Ther 302:1253-1264
2. Beattie DT, Cheruvu M, Mai N, O'Keefe M, Johnson-Rabidoux S, Peterson C, Kaufman E, Vickery R (2007) The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011 and methylnaltrexone. Naunyn-Schmiedeberg's Arch Pharm 375:205-220
3. Beattie D, Vickery R, Armstrong S, Campbell C, Richardson C, Tsuruda P, Mai N, Shen F (2010) TD-1211, a potent and peripherally-selective μ-opioid receptor antagonist. Poster #PW262, 13th World Congress on Pain, Montreal, Canada
4. Beattie DT, Armstrong SR, Vickery RG, Tsuruda PR, Campbell CB, Richardson C, McCullough JL, Daniels O, Yu-Ping L, Kim KHS (2011) The pharmacology of TD-8954, a potent and selective 5-HT4 receptor agonist with gastrointestinal prokinetic properties. Front Pharm 2:1-13
5. Bianchetti A, Giudice A, Nava F, Manara L (1986) Dissociation of morphine withdrawal diarrhea and jumping in mice by the peripherally selective opioid antagonist SR 58002 C. Life Sci 39:2297-2303
6. Brown DR, Goldberg LI (1985) The use of quaternary narcotic antagonists in opiate research. Neuropharm 24:181-191
7. Camilleri M (2005) Alvimopan, a selective peripherally acting [mu]-opioid antagonist. Neurogastroenterol Motil 17:157-165
8. Camilleri M (2011) Opioid-induced constipation: challenges and therapeutic opportunities. Am J Gastroenterol 106:835-842
9. Dehaven-Hudkins D, Burgos L, Cassel J, Daubert J, Dehaven R, Mansson E, Nagasaka H, Yu G, Yaksh T (1999) Loperamide (ADL 2-1294), an opioid antihyperalgesic agent with peripheral selectivity. J Pharm Exp Ther 289:494-502
10. Espejo EF, Stinus L, Cador M, Mir D (1994) Effects of morphine and naloxone on behaviour in the hot plate test: an ethopharmacological study in the rat. Psychopharm 113:500-510
11. Fioramonti J, Fargeas M-J, Bueno L (1987) Stimulation of gastrointestinal motility by loperamide in dogs. Dig Dis Sci 32:641-646
12. Foss JF (2001) A review of the potential role of methylnaltrexone in opioid bowel dysfunction. Am J Surg 182:19S-26S
13. Foss J, Schmith V, Wallin B, Du W, Melikian A (2005) Alvimopan (Entereg™), a novel opioid antagonist, achieves active systemic concentrations. Clin Pharm Ther 77:P74
14. Jaffe J, Martin W (1990) Opioid analgesics and antagonists. In: Gilman A, Rall T, Nies A, Taylor P (eds) Goodman and Gilman's the pharmacological basis of therapeutics, 8th edn. Pergamon, New York, pp 485-521
15. Kest B, Palmese CA, Hopkins E, Adler M, Juni A, Mogil JS (2002) Naloxone-precipitated withdrawal jumping in 11 inbred strains: evidence for common genetic mechanisms in acute and chronic morphine physical dependence. Neurosci 11:463-469
16. Koslo RJ, Vaught JL, Cowan A, Gmerek DE, Porreca F (1985) Intrathecal morphine slows gastrointestinal transit in rats. Eur J Pharm 119:243-246
17. Kotake A, Kuwahara S, Burton E, McCoy C, Goldberg L (1989) Variations in demethylation of N-methylnaltrexone in mice, rats, dogs, and humans. Xenobiotica 19:1247-1254
18. Moss J, Rosow CE (2008) Development of peripheral opioid antagonists: new insights into opioid effects. Mayo Clin Proc 83:1116-1130
19. Murphy D, Sutton J, Prescott L, Murphy M (1997) Opioid-induced delay in gastric emptying: a peripheral mechanism in humans. Anesthesiology 87:765-770
20. Niemegeers CJE, Lenaerts FM, Janssen PAJ (1974) Loperamide (R 18 553), a novel type of antidiarrheal agent. part 2: in vivo parenteral pharmacology and acute toxicity in mice: comparison with morphine, codeine, and diphenoxylate. Arzneim-Forsch/Drug Res 24:1636-1641
21. Niemegeers CJE, Colpaert FC, Awouters F (1981) Pharmacology and antidiarrheal effect of loperamide. Drug Dev Res 1:1-20
22. Schmidt WK (2001) Alvimopan*(ADL 8-2698) is a novel peripheral opioid antagonist. Am J Surg 182:27S-38S
23. Schmith V, Garnett W, Barr W, Kelleher D, Young M, Sanderlin G, Coots S, Agyemang A, Dukes G (2005) Alvimopan pharmacokinetics (PK) & pharmacodynamics (PD) in patients with chronic constipation. Clin Pharm Ther 77:P49
24. Sloots CE, Rykx A, Cools M, Kerstens R, De Pauw M (2010) Efficacy and safety of prucalopride in patients with non-cancer pain suffering from opioid-induced constipation. Dig Dis Sci 55:2912-2921
25. Tsuruda P, Vickery R, Armstrong S, Long D, Beattie D (2013) The in vitro pharmacological profile of TD-1211, a neutral opioid receptor antagonist. Naunyn-Schmiedeberg's Arch Pharm. doi: 10.1007/s00210-013-0850-7
26. Turner RA (1965) Screening methods in pharmacology. Academic, New York, pp 142-144
27. Vickery R, Yu-Ping L, Schwertschlag U, Singla N, Webster L, Canafax D (2012) TD-1211 demonstrates improvement in bowel movement frequency without impacting analgesia in a phase 2b study of patients with opioid-induced constipation. PainWeek 2012, Las Vegas, NV. September 5-8, 2012. Poster #121
28. Webster L, Dhar S (2009) NKTR-118 significantly reverses opioid-induced constipation. Poster, 20th AAPM Annual Clinical Meeting, Phoenix, AZ
29. Wong BS, Camilleri M (2011) Lubiprostone for the treatment of opioid-induced bowel dysfunction. Expert Opin Pharmacother 12:983-990
30. Yuan CS (2004) Clinical status of methylnaltrexone: a new agent to prevent and manage opioid-induced side effects. J Support Oncol 2:111-122
31. Zimmerman DM, Gidda JS, Cantrell BE, Werner JA, Parli CJ, Franklin RB, Francis PC, Means JR, Pohland RC, Leander JD (1994) LY246736 dihydrate: mu opioid receptor antagonist. Drugs Future 19:1078-1083